Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05939700 · ClinicalTrials.gov registry record

Mavacamten Pregnancy Surveillance Program

A clinical trial of Pregnancy Related and Breastfeeding, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT05939700 is a study of Pregnancy Related and Breastfeeding that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 20 participants, below the 1,963-participant average among 99 other Pregnancy Related trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05939700, a study of Pregnancy Related and Breastfeeding, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or breastfeeding.

Interventions

  • DRUG Mavacamten

Study Locations (1)

North Carolina

  • The Mavacamten Pregnancy Surveillance Program, PPD Inc - Wilmington

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-11-09
Est. Completion 2027-04-30

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT05939700

The ClinicalTrials.gov registry entry for NCT05939700 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,963-participant average among 99 other Pregnancy Related trials with a reported enrollment target (99% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pregnancy Related appearing as the primary indexed condition, and to 1 intervention - of which Mavacamten is the first listed.

NCT05939700 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05939700 about?

NCT05939700 is a clinical study titled "Mavacamten Pregnancy Surveillance Program". The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or breastfeeding.

What is the current status of trial NCT05939700?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2023-11-09. Estimated completion is 2027-04-30.

What conditions does trial NCT05939700 study?

This clinical trial studies the following conditions: Pregnancy Related, Breastfeeding, Hypertrophic Cardiomyopathy.

What interventions are being tested in trial NCT05939700?

The interventions under investigation include: Mavacamten (DRUG).

Who is sponsoring clinical trial NCT05939700?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05939700 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pregnancy Related

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.